1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Thyroid Cancer: Disease and Pipeline Analysis

Thyroid Cancer: Disease and Pipeline Analysis

  • August 2014
  • -
  • Industry Standard Research
  • -
  • 91 pages

This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the thyroid cancer market not available elsewhere. This report gives an overview of the current and future thyroid cancer clinical development market, the activities of the key market players, and outlines trial and commercial regulatory environments.

Report Overview

This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the thyroid cancer market not available elsewhere. This report gives an overview of the current and future thyroid cancer clinical development market, the activities of the key market players, and outlines trial and commercial regulatory environments.

What you will learn in this report:

• Global and country-specific incidence rates for thyroid cancer
• Active development pipeline, including promising new therapies currently in Early and Late Phases of development
• Analysis of clinical trial environments for new thyroid cancer therapies
• Areas of unmet need

How you can use this report:

• Identify and enhance commercial and development opportunities with an in-depth and current analysis of the global thyroid cancer market
• Understand how products currently in development could impact this market
• Assess the competition with an analysis and summary of companies active in this space

Table Of Contents

Thyroid Cancer: Disease and Pipeline Analysis
Table of Contents

Copyright and Usage Guidelines ..6
Chapter 1 - Thyroid Cancer Disease Overview 9
Differentiated Thyroid Carcinoma (DTC) ...11
Medullary Thyroid Carcinoma (MTC) 11
Poorly Differentiated Thyroid Carcinoma (PDTC) .12
Anaplastic Thyroid Carcinoma (ATC) .13
Other Thyroid Cancer Types ..12
Thyroid Cancer Risk Factors ..13
Radiation ...14
Gender and Age 14
Levels of Dietary Iodine 14
Hereditary Conditions and Family History 14
Obesity ..14
History of Goitre ...14
Infographic: ...15
Chapter 2 - Thyroid Cancer Epidemiology .16
Thyroid Cancer Incidence ...17
Thyroid Cancer Mortality ...22
Chapter 3 - Thyroid Cancer Diagnosis and Staging 24
Initial Patient Assessment ..25
Symptoms ..25
Physical examination ..26
Biopsy .27
Imaging tests ..28
Ultrasound ..28
Radioiodine scan 28
Chest x-ray ..29
Computed tomography (CT) scan ..29
Positron emission tomography (PET) scan .29
Blood tests ..30
Molecular Markers .30
Chapter 4 - Thyroid Tumour Classification 33
Differentiated Thyroid Cancer ...35
Anaplastic Thyroid Cancer .36
Chapter 5 - Treatment of Thyroid Cancer .38
Surgery for thyroid cancer .39
Thyroidectomy and Lymph Node Removal 39
Lobectomy .39
Radioactive iodine (radioiodine) therapy for thyroid cancer .40
Thyroid hormone therapy ..41
External beam radiation therapy ...42
Chemotherapy ...43
Targeted systemic therapy .44
Sorafenib Tosylate (Nexavar) .44
Vandetanib (Caprelsa) ...45
Cabozantinib-S-Malate (Cometriq) .46
Comparison of Vandetanib and Cabozantinib 47
Treatment by Disease Stage and Type ...49
Differentiated Thyroid Cancer 49
Medullary Thyroid Cancer ..50
Poorly Differentiated Thyroid Carcinoma ...50
Anaplastic Thyroid Cancer ..51
Patient Follow-up 52
Differentiated Thyroid Cancer 52
Medullary Thyroid Cancer ..52
Anaplastic Thyroid Cancer ..53
Chapter 6 Thyroid Cancer Prognosis ..54
Chapter 7 Environmental Analysis .57
Areas of Unmet Need 58
A Problem of Over-diagnosis? ...58
Diagnostic Techniques ...59
Lack of Effective Therapies for Advanced Stage Disease ...59
Poor Prognosis for Anaplastic Thyroid Cancer ..59
Major Market Analysis ..60
Trial and Recruitment Environment ..61
Regulatory Environment ...61
Competitive Product Landscape ...62
Pricing and Reimbursement Environment 63
Emerging Market Analysis .65
Trial and Recruitment Environment ..65
Regulatory Environment 67
Competitive Product Landscape 68
Pricing and Reimbursement Environment 68
Patient Recruitment Environment .70
Drug Development Field 75
Chapter 8 Drug Development in Thyroid Cancer ...76
New Therapies in Active Development for the Treatment of Thyroid Cancer ...80
Lenvatinib (E7080), Eisai 81
Selumetinib, AstraZeneca ..82
Vandetanib (Caprelsa), AstraZeneca ..82
Vemurafenib, Roche ..83
GSK2118436, GSK ..84
Ponatinib (Iclusig), Ariad Pharma ..85
Fosbretabulin tromethamine (Zybrestat), OxiGene ..85
VB-111, VBL Therapeutics .86
GI-6207, GlobeImmune Inc/Celgene .86
Citations .88
Thyroid Cancer Diagnosis and Treatment Guidelines 89
About Industry Standard Research 91

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Epiomic Epidemiology Series: Cervical Cancer Forecast in 22 Major Markets 2016 - 2026

Epiomic Epidemiology Series: Cervical Cancer Forecast in 22 Major Markets 2016 - 2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Cervical Cancer in 22 Major Markets Cervical cancer (ICD-10 code C53, cervix uteri) is a type of cancer that occurs in the cells of ...

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

  • $ 4995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market

  • January 2017
    19 pages
  • Therapy  

    Anticoagulant  

    Cancer  

View report >

Cancer Statistics in Denmark

  • January 2017
    6 pages
  • Therapy  

  • Denmark  

View report >

Hormone and Therapy Market in Pakistan and the US

  • January 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Related Market Segments :

Cancer
Therapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.